RhumbLine Advisers’s Addex Therapeutics ADXN Stock Holding History

RhumbLine Advisers’s Portfolio ADXN Stock Details ADXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-72	Closed	-$450	–	4131
2026 Q1	$450	Hold	72	–	–	﹤0.01%	4015
2025 Q4	$554	Hold	72	–	–	﹤0.01%	4053
2025 Q3	$655	Hold	72	–	–	﹤0.01%	4049
2025 Q2	$637	Hold	72	–	–	﹤0.01%	4059
2025 Q1	$528	Sell	72 -35	-33%	-$271	﹤0.01%	4053
2024 Q4	$749	Buy	107 +72	+206%	+$656	﹤0.01%	4085
2024 Q3	$337	Buy	+35	New	+$312	﹤0.01%	4135

Other funds holding ADXN

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

RhumbLine Advisers's ADXN Position: Q2 2026 in Review

RhumbLine Advisers sold out of Addex Therapeutics (ADXN) in Q2 2026, closing a stake of 72 shares — an estimated $450 sold.

RhumbLine Advisers first reported a position in ADXN in Q3 2024 and held it in 7 quarters. The position peaked at $749 in Q4 2024. 2 funds tracked by Wall St. Rank hold ADXN as of Q2 2026.

RhumbLine Advisers reported no remaining Addex Therapeutics position as of Q2 2026 after selling out during the quarter.
RhumbLine Advisers sold 72 Addex Therapeutics shares in Q2 2026, an estimated $450.
RhumbLine Advisers first reported a position in Addex Therapeutics in Q3 2024 and held it in 7 quarters.
RhumbLine Advisers's Addex Therapeutics position peaked at $749 in Q4 2024.
2 funds tracked by Wall St. Rank held Addex Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.